Clear Search

Showing 3 results for “Chertow GM”.

February 2023

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Diabetes Care. 2023; online ahead of print DOI: 10.2337/dc22-1514

Achieving optimal glucose control can be challenging in patients with T2D and CKD because impaired kidney function hampers the use of several oral or injectable glucose-lowering therapies (GLTs) and increases the likelihood of hypoglycaemia. This prespecified analysis from the DAPA-CKD trial evaluated whether the benefits of dapagliflozin in patients with T2D and CKD varied by background GLT number or class.

more…

March 2022

Dapagliflozin and New-Onset Type 2 Diabetes in Patients With Chronic Kidney Disease Or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials

Lancet Diabetes Endocrinol 2022;10:24–34 doi.org/10.1016/

Chronic kidney disease and heart failure are insulin resistant states associated with high incidence rates of diabetes. Rossing et al. carried out a two Phase 3, randomised, double-blind, placebo-controlled trials assessed the effect of dapagliflozin on new-onset type 2 diabetes, in a pooled analysis of data from 6,608 individuals. 


more…

January 2022

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial

Nephrol Dial Transplant. 2021 Nov 25;gfab335. DOI: 10.1093/ndt/gfab335.

This study by Wheeler et al. found that dapagliflozin numerically, but not significantly, reduced the rate of chronic decline of eGFR compared to placebo among DAPA-CKD participants with FSGS.

more…